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Abstract: This retrospective population-based study examined the impact of age and comorbid-
ity burden on multimodal management and survival from colorectal cancer (CRC). From 2000 to
2015, 1479 consecutive patients, who underwent surgical resection for CRC, were reviewed for
age-adjusted Charlson comorbidity index (ACCI) including 19 well-defined weighted comorbidi-
ties. The impact of ACCI on multimodal management and survival was compared between low
(score 0–2), intermediate (score 3) and high ACCI (score ≥ 4) groups. Changes in treatment from
2000 to 2015 were seen next to a major increase of laparoscopic surgery, increased use of adjuvant
chemotherapy and an intensified treatment of metastatic disease. Patients with a high ACCI score
were, by definition, older and had higher comorbidity. Major elective and emergency resections for
colon carcinoma were evenly performed between the ACCI groups, as were laparoscopic and open
resections. (Chemo)radiotherapy for rectal carcinoma was less frequently used, and a higher rate
of local excisions, and consequently lower rate of major elective resections, was performed in the
high ACCI group. Adjuvant chemotherapy and metastasectomy were less frequently used in the
ACCI high group. Overall and cancer-specific survival from stage I-III CRC remained stable over
time, but survival from stage IV improved. However, the 5-year overall survival from stage I–IV
colon and rectal carcinoma was worse in the high ACCI group compared to the low ACCI group.
Five-year cancer-specific and disease-free survival rates did not differ significantly by the ACCI. Cox
proportional hazard analysis showed that high ACCI was an independent predictor of poor overall
survival (p < 0.001). Our results show that despite improvements in multimodal management over
time, old age and high comorbidity burden affect the use of adjuvant chemotherapy, preoperative
(chemo)radiotherapy and management of metastatic disease, and worsen overall survival from CRC.
Keywords: elderly; comorbidity; colorectal cancer; survival
1. Introduction
Colorectal carcinoma (CRC) is the third most common cancer worldwide [1,2] and the
fourth leading cause of cancer death [1,2]. Over the years, many improvements have been
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made in the management of colorectal cancer [3–8]. These include diagnostic procedures,
use of laparoscopic surgery, improvements in perioperative care, refinement of histopatho-
logical examination and the development of effective neoadjuvant, adjuvant and palliative
treatments and extended indications for resection of metastatic disease.
CRC incidence increases markedly with increasing age as do the prevalence of chronic
comorbid conditions [1]. Due to frequent medical comorbidities and aging-related dimin-
ished physiological reserves, elderly patients are considered at higher risk for complications
from major cancer surgery and chemotherapy and, therefore increase the complexity of
multimodal management of colorectal cancer. In particular, comorbidity may lead to
altered treatment, higher morbidity rates and worse survival [9–11].
The age-adjusted Charlson comorbidity index (ACCI) is a measure of comorbidity
used to standardize the evaluation of surgical patients [12–14], and has been reported
to be an appropriate prognostic factor for pancreatic, gastric and colorectal cancer pa-
tients [15–22]. The age-adjusted Charlson comorbidity index includes 19 well-defined
comorbidities and age as an additional factor [14]. The objectives of the current study were
to assess the impact of age and comorbidity burden (ACCI) on multimodal treatment and
survival from CRC by retrospectively reviewing all diagnosed colorectal cancers from 2000
to 2015 in Central Finland.
2. Materials and Methods
According to Finnish healthcare policy, all municipalities are responsible for arranging
specialized hospital care for their residents. Each hospital district organizes and provides
specialized hospital care for the population in its area. The Central Hospital of Central
Finland is the only gastroenterological surgery unit in the Central Finland hospital district.
All patients with primary and metastatic colorectal cancer are managed in this hospital,
with no referrals to other hospitals. The annual population of the area, obtained from
Statistics Finland, averaged around 270,000 during the study period from 2000 to 2015.
2.1. Patients
Patients diagnosed with primary colorectal adenocarcinoma from 2000 to 2015 were
identified using the histopathological registry of the hospital. Included in the study were
patients who underwent resectional surgery for primary colorectal adenocarcinomas, de-
fined as removal of primary tumor. Right-sided colon cancers were defined as those arising
from the cecum to, and including, the transverse colon. Left-sided colon cancers were
defined as those arising from the splenic flexure down to, and including, the rectosigmoid
junction. Tumors located 15 cm or less from the anal verge were considered rectal cancers.
Colonoscopy, thoracoabdominal computed tomography (CT), endorectal ultrasonog-
raphy and pelvic magnetic resonance imaging (MRI) were used to diagnose and stage
primary colorectal tumors. All patients with colorectal cancer were discussed in multidisci-
plinary team (MDT) meetings before definitive treatment decisions were made.
2.2. Surgical Procedures
Multimodal management was done according to international guidelines [3–8]. Sig-
nificant co-morbidity, inadequate physical and mental performance status and extensive
metastatic disease were contraindications for surgery. Patients who were not resected
had non-resectional procedures that were purely diagnostic or symptom-alleviating (e.g.,
stoma), were excluded.
Laparoscopic surgery for colorectal cancer was implemented in 2001 after an ini-
tial experience of some 100 laparoscopic colorectal procedures for benign diseases since
1993. Details of our surgical technique, including right or left hemicolectomies, extended
hemicolectomies or sigmoid resections with wide mesocolic excision [23,24] and rectal
resections according to total mesorectal excision (TME) principles [25], have been described
earlier [26,27].
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Cancer invasion to uncommon sites including urinary bladder, uterus, ovary or
abdominal wall and some emergency situations were treated with extended surgery, when
appropriate. Laparoscopic transanal total mesorectal excision (TaTME) was experimentally
undertaken in a few patients during 2010–2015. Local endoscopic or transanal excisions for
malignant polyps were considered radical for stage I tumors alone. Surgery for metastatic
disease was performed when appropriate, according to local MDT. Tumors were staged by
staff pathologists according to the TNM/UICC (The Union for International Cancer Control)
classification [28]. The quality of the pathological examination was refined since 2005.
2.3. Neoadjuvant and Adjuvant Treatments
Adjuvant postoperative chemotherapy for 6 months, consisting of 5-fluorouracil (5-
FU) and folic acid, a combination of oxaliplatin with fluorouracil (FOLFOX) or capecitabine
(CAPOX) or capecitabine alone for elderly patients, was prescribed to medically fit patients
with stage III tumors or high-risk stage II disease. Patients with locally advanced rectal
cancer on endorectal ultrasound and magnetic resonance imaging received either a short-
course radiotherapy (RT) (5 Gy × 5) followed by surgery within a week or a long-course
chemoradiation (1.8 Gy × 25 or 2 Gy × 25 with capecitabine) followed by surgery after 6–8
weeks. A short-course radiotherapy combined with neoadjuvant chemotherapy (FOLFOX
or CAPOX) and delayed surgery was used selectively between 2005–2015 for rectal cancer
(8). Patients with liver metastases received perioperative chemotherapy with the FOLFOX
regimen, with or without biologicals, according to the decision taken at the MDT meeting.
2.4. Follow-Up
Follow-up after surgery for primary tumors included initially carcinoembryonic anti-
gen estimation, clinical examination, ultrasound investigation of the liver, and chest radio-
graphy every 6 months during the first 3 years, and annually thereafter. Since 2005 chest
radiography and ultrasound investigation were replaced by CT. Further characterization
of metastases was undertaken by MRI, and after 2005 also by CT–PET (positron emission
tomography). Locally recurrent disease was assessed by endoscopy, CT/pelvic MRI and
endoscopy. Local recurrence from colon cancer included all peritoneal and/or lymph node
metastases in the abdomen. Local recurrence from rectal cancer included recurrences in the
small pelvis. All patients included in this study were followed up from time of diagnosis
until death or until November, 2020. The date and cause of death were obtained from the
medical records and verified from the National Cause of Death Registry.
2.5. Data Collection, Assessment of Age-Adjusted Charlson Comorbidity Index and
Outcome Measures
Clinical and histopathological data, as well as recurrence data, were retrieved ret-
rospectively from electronic hospital records. The study variables for primary tumors
included age, sex, Charlson comorbidity, date of diagnosis, tumor sidedness and loca-
tion, UICC stage, date and type of surgery, radiotherapy, oncological treatment and sur-
vival. Trends in multimodal treatment and survival were examined between 2000–2005,
2006–2010 and 2011–2015. ACCI score was used to quantify weighted comorbidities as
summary measures including 19 well-defined comorbidities and age as one additional
factor (Table 1) [12–14]. The final score was calculated for each patient by taking into
account all comorbid conditions present with the exclusion of present colorectal cancer
was. Median ACCI score of all CRC patients was 3 (interquartile range (IQR) 2–4). The
impact of ACCI on multimodal management and survival was compared between low
(score 0–2), intermediate (score 3) and high ACCI (score ≥4) groups. Analyses were per-
formed for age, gender, comorbidity, sidedness (right vs. left) and location (right vs. left
vs. rectum), stage distribution, multimodal treatment, local recurrence, metastatic disease
and survival. The study was approved by the hospital administrative and ethics board
(Dnro13U/2011 and 1/2016 and the National Authority for Welfare and Health (Valvira)
(Dnro 3916/06.01.03.01/2016).
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Table 1. Age-adjusted Charlson comorbidity index and comorbidity weighting.
Weight Charlson Comorbid Condition
1
Myocardial infarction, congestive heart failure, peripheral or cerebral
vascular disease, TIA (transient ischemic attack), chronic obstructive
pulmonary disease (COPD), connective tissue disease, mild liver disease,
peptic ulcer disease, diabetes, dementia
2 Hemiplegia, moderate/severe renal disease, diabetes with end-organdamage, previous cancer *, leukemia, lymphoma
3 Moderate or severe liver disease
6 Metastatic solid cancer *, Acquired Immunodeficiency Syndrome (AIDS)
1 For each decade over age 50 years, up to 4 points
* if treated previously before the diagnosis of present colorectal cancer.
2.6. Statistical Analysis
Results are given as mean (standard deviation (s.d.)) or median (IQR) values. Pear-
son’s χ2 or Fisher’s exact tests were used to compare frequencies, analysis of variance
(ANOVA) test for comparison of mean values between groups, and Kruskal–Wallis test for
comparison of median values between independent samples. The Kaplan–Meier method
was used to calculate survival, and differences between groups were compared with the
log rank test. Survival times were calculated from the date of primary surgery to the
date of death or the end of follow-up November, 2020. Overall survival (OS) included
all causes of death. Cancer-specific survival (CSS) included deaths from CRC or its treat-
ment. Disease-free survival was calculated from the date of surgery to the first record
of metastasis or local recurrence, and censored to death or to end of follow-up without
recurrence. As the number of patients with rectal cancer and a complete pathological
response after chemoradiotherapy was small, these patients were included with stage I
patients for purposes of survival analyses. Factors affecting survival were analyzed with
univariate and multivariable Cox proportional hazards regression models; only variables
with p < 0.20 were entered in the multivariate analysis. All statistical tests were two-sided.
p < 0.050 was considered significant. STATA® release 13 (Stata Corp, College Station, TX,
USA) was used for statistical analysis.
3. Results
Of the 1680 CRC patients referred to the hospital between 2000–2015, 1479 under-
went resective surgery in the multimodal setting, whereas 201 primary cancers (12.0%)
were not operated on, either because of significant co-morbidity, old age and poor perfor-
mance status, locally unresectable primary cancer, unresectability of metastases or patient’s
preference.
3.1. Patient Characteristics and Tumor Stage Distribution According to Age-Adjusted Charlson
Comorbidity Index (ACCI) Score
The proportion of colon cancers, particularly right-sided cancers, increased over time
compared to rectal cancers. Baseline patient characteristics and UICC stage distribution of
colon (p = 0.044) and rectal (p = 0.126) carcinoma according to ACCI groups are presented
in Table 2. The incidence of right-sided colon cancers, medical comorbidities and older age
was most frequent in the high ACCI group.
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Table 2. Patient characteristics and tumor stage distribution by low, intermediate and high age-
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Figure are n (%) unless otherwise stated; a pCR = pathologic complete response.
3.2. Multimodal Treatment
Changes in treatment over time were seen next to a major increase of laparoscopic
surgery, increased use of adjuvant chemotherapy and an intensified treatment of metastatic
disease with a shift to an increased use of neoadjuvant chemotherapy and metastasectomy,
particularly for rectal carcinoma (supplementary Figure S1a,b). Surgical treatment of colon
cancer patients with more severe comorbidities increased significantly over time (37.5% vs.
51.6%, p < 0.001). A similar time trend was not seen in rectal cancer patients.
The influence of ACCI on multimodal treatment is presented in Figure 1A,B. Major
elective, emergency and local resections for colon carcinoma were evenly performed between
the three ACCI groups as were laparoscopic and open resections. (Chemo)radiotherapy
for rectal carcinoma was less frequently used, and a higher rate of local excisions and
consequently a lower rate of major elective resections was performed in the high ACCI
group. Thirty-day mortality after surgery for colon carcinoma in the low, intermediate
and high ACCI groups was 0.6%, 0.4% and 6.0%, p < 0.001, and 30-day morbidity 18.0%,
22.2% and 31.4%, respectively, p < 0.001. The respective figures for rectal cancer were
not significantly different: 30-day mortality by the low, intermediate and high ACCI was
1.0%, 0.7% and 3.0%, p = 0.190, and 30-day morbidity 39.7%, 34.3% and 35.3%, respectively,
p = 0.528.
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Figure 1. Multimodal management for colon (A) and rectal (B) carcinoma by low, intermediate and
high ACCI groups. Bars represent n (%) except p-values.
The administration of adjuvant chemotherapy for stages II–III colon carcinoma was
less frequent in the high ACCI group. As for rectal cancer, administration of adjuvant
chemotherapy was reduced for stage II in the high ACCI group but n t for stage III.
Local recurrences after surgery for stages I–III colon and rectal carcinoma, excluding
patients who died within 30-days postoperatively, were evenly distributed in the ACCI
groups (Figure 1A,B). The incidence of metastatic disease, observed in some 30% of patients
over time, was lower in the high ACCI group for colon cancer but not for rectal cancer.
Despite increased use of neoadjuvant chemotherapy and metastatic surgery over time,
metastatic patients in the high ACCI group received metastatic surgery less often than
other patients.
3.3. Long-Term Survival
The median follow-up time for patients after resection for colon carcinoma was 6.4
years (IQR 2.3–10.6) years and for rectal carcinoma 7.0 (IQR 3.3–11.4) years. Of the deaths
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that occurred during the follow-up, non-cancer-related mortality for colon cancer was
30.6% and cancer progression-related mortality 28.8%. Non-cancer-related mortality for
rectal cancer was 30.3% and cancer progression-related mortality 25.8%.
Five-year OS from stages I–IV colon and rectal carcinoma was worse in the high
ACCI group compared to low and medium ACCI groups: For colon (Figure 2A), the OS
was 71.5% for low ACCI, 71.1% for intermediate ACCI and 49.8% for high ACCI. For
rectum (Figure 2B) the OS was 74.4%, 67.8% and 60.4%, respectively. Five-year CSS by low,
intermediate and high ACCI from stages I–IV colon was 75.9%, 77.2% and 68.9% (p = 0.056)
and from rectal cancer 78.3%, 79.1% and 79.4% (p = 0.913), respectively. Five-year disease-
free survival (DFS) by low, intermediate and high ACCI from stages I–III colon cancer was
78.3%, 80.5% and 80.1% (p = 0.904) and from stages I–III rectal cancer 75.9%, 74.4 and 76.5
(p = 0.788), respectively.
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 7 of 13 
 
 
The median follow-up time for patients after resection for colon carcinoma was 6.4 
years (IQR 2.3–10.6) years and for rectal carcinoma 7.0 (IQR 3.3–11.4) years. Of the deaths 
that occurred during the follow-up, non-cancer-related mortality for colon cancer was 
30.6% and cancer progression-related mortality 28.8%. Non-cancer-related mortality for 
rectal cancer was 30.3% and cancer progression-related mortality 25.8%.  
Five-year OS from stages I–IV colon and rectal carcinoma was worse in the high 
ACCI group compared to low and medium ACCI groups: For colon (Figure 2A), the OS 
was 71.5% for low ACCI, 71.1% for intermediate ACCI and 49.8% for high ACCI. For 
rectum (Figure 2B) the OS was 74.4%, 67.8% and 60.4%, respectively. Five-year CSS by 
low, intermediate and high ACCI from stages I–IV colon was 75.9%, 77.2% and 68.9% (p = 
0.056) and from rectal cancer 78.3%, 79.1% and 79.4% (p = 0.913), respectively. Five-year 
disease-free survival (DFS) by low, intermediate and high ACCI from stages I–III colon 
cancer was 78.3%, 80.5% and 80.1% (p = 0.904) and from stages I–III rectal cancer 75.9%, 
74.4 and 76.5 (p = 0.788), respectively. 
In multivariable Cox proportional hazard analysis (Table 3) ACCI, male gender, 
UICC stage and type of surgery at pres ntation were independent prognostic factors for 
colon carcinoma and UICC stage and ACCI for rectal carcinoma overall survival. 
 
Figure 2. Five-year overall from stages I–IV colon carcinoma (A) and rectal carcinoma (B). 
Table 3. Univariate and multivariable Cox proportional hazard analysis for overall survival. 
 
Univariate 























Figure 2. Five-year ove all from stages I–IV colon carcin ma (A) and rect l carcinoma (B).
In multivariable Cox proportional hazard analysis (Table 3) ACCI, male gender, UICC
stage and type of surgery at presentation were independent prognostic factors for colon
carcinoma and UICC stage and ACCI for rectal carcinoma overall survival.
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Low 1 <0.001 1 <0.001
Intermediate 1.30 (1.02–1.66) 1.50 (1.17–1.92)
High 2.70 (2.21–3.30) 3.24 (2.65–3.98)
Gender
Male 1 0.032 1 0.026
Female 0.84 (0.71–0.98) 0.82 (0.69–0.97)
UICC stage
I 1 <0.001 1 <0.001
II 1.25 (0.97–1.63) 1.31 (1.00–1.73)
III 1.53 (1.18–1.20) 1.71 (1.29–2.26)
IV 7.34 (5.47–9.83 ) 8.75 (6.38–11.99)
Type of surgical resection
Elective major surgery 1 <0.001 1 <0.001
Emergency surgery 2.21 (1.72–2.83) 1.82 (1.41–2.35)
Local excision 1.36 (0.75–2.48) 1.90 (1.0–3.62)
Adjuvant chemotherapy
No 1 0.254 _
Yes 0.90 (0.76–1.07)
Side of colon
Right 1 0.141 1 0.077
Left 0.88 (0.75–1.04) 0.86 (0.72–1.02)
Time periods
2000–2005 1 0.707




Low 1 <0.001 1 <0.001
Intermediate 1.81 (1.33–2.45) 2.25 (1.65–3.07)
High 2.51 (1.89–3.34) 3.29 (2.42–4.36)
Gender
Male 1 0.320 _
Female 0.88 (0.69–1.13)
UICC stage
I 1 <0.001 1 <0.001
II 1.33 (0.98–1.80) 1.41 (1.04–1.91)
III 1.59 (1.16–2.16) 1.90 (1.39–2.60)
IV 5.51 (3.73–8.15) 8.42 (5.60–12.67)
Type of surgical resection
Elective major surgery 1 0.543 _
Emergency surgery 3.11 (1.46–6.60)
Local excision 1.01 (0.58–1.76)
Preoperative radiotherapy
No radiotherapy 1 0.296 _
Short-course (25 Gy) 0.87 (0.65–1.16)
Chemoradiotherapy (50 Gy) 1.17 (0.89–1.55)
Adjuvant chemotherapy
No 1 0.601 _
Yes 1.07 (0.83–1.39)
Time periods
2000–2005 1 0.483 _
2006–2010 1.01 (0.76–1.34)
2011–2015 0.89 (0.66–1.22)
* p for linearity.
4. Discussion
This retrospective population-based study aimed to examine whether or not the
combined effect of age and comorbidity, assessed by the age-adjusted Charlson comorbidity
index, had a clinical impact on multimodal management and survival from colorectal
cancer. The main findings of the present study were that preoperative radiotherapy,
adjuvant chemotherapy, postoperative mortality and morbidity, management of metastatic
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disease and overall survival were adversely influenced by old age and high Charlson
comorbidity burden despite improvements in multimodal therapy and management of
metastatic disease over time.
Due to population aging, an increasing proportion of elderly patients and comor-
bid conditions was observed over time in our study, particularly for colon cancer. The
proportion of elderly patients and comorbidity was in our series consistent with other
studies [17–19,29]. A preponderance of right-sided colon cancers was observed here in line
with international trends. About one third of colorectal cancers originated in the rectum,
and the rates were higher in men than in women. Proportional UICC stage distribution
was relatively evenly distributed between different age-adjusted comorbidity groups.
Changes in treatment from 2000 to 2015 were seen next to a major increase of la-
paroscopic surgery, increased use of adjuvant chemotherapy and an intensified treatment
of metastatic disease with a shift to an increased use of neoadjuvant chemotherapy and
metastasectomy, particularly for rectal carcinoma. Laparoscopic and open resections were
evenly distributed between the ACCI groups.
There are interactions between general health status and indications for and tolerability
of neoadjuvant and adjuvant treatments, especially in elderly patients. Elderly patients
with CRC tend to be underepresented in clinical trials and undertreated in clinical practice.
Therefore, the extent to which patients older than 75 years benefit from postsurgical
chemotherapy remains a challenge that is frequently encountered in oncology practice [30].
The use of postoperative systemic therapy is generally recommended for Stage III and high
risk Stage II colon cancer, but no randomized trials have demonstrated similar gains in the
younger and elderly population [31,32]. In addition, the use of postoperative chemotherapy
in patients with rectal cancer receiving preoperative radio(chemo)therapy is not based on
strong scientific evidence [4,8]. Although the administration of adjuvant chemotherapy
increased here during more recent time periods, it was less frequently used in the high
ACCI group. A similar trend has been reported by others [11,32].
The use of preoperative (chemo)radiotherapy for rectal carcinoma has not demon-
strated an overall survival benefit in randomized trials, but induces tumor regression with
a possible complete response (pCR) and reduced local recurrence rate [8]. The adminis-
tration of preoperative (chemo)radiotherapy for locally advanced rectal cancer was in our
series constant between 2000–2015 but was reduced in the high ACCI group. The optimal
radiotherapy fractionation and interval between radiotherapy and surgery is still under
debate [8]. The Stockholm III trial has shown that delaying surgery for 4–8 weeks after short-
course RT, rather than operating immediately, may reduce postoperative complications
significantly. The short-course radiotherapy combined with neoadjuvant chemotherapy
and delayed surgery was used here selectively since 2008 for rectal cancer.
Indicators of quality of treatment, e.g., proportion of patients operated in an emergency
setting, risk of postoperative mortality and complications and locoregional recurrence were
in agreement with the findings from previous studies. The rate of surgical emergency,
usually bowel obstruction and/or perforation, resulting in higher mortality, increased
local recurrence rate and worse survival, was in our series 10% in contrast to 17–29% of
patients reported internationally [33]. Postoperative mortality rate in this patient series,
including also emergency surgery, was low and within the reported range of 2–5% from
other European countries [34–36]. The increase in postoperative mortality with advancing
age may be partly explained by comorbidity. The overall short-term morbidity was in
line with other reports [36], but was higher especially among older patients with high
comorbidity. Local recurrence rate after colon and rectal surgery remained relatively stable
over time, and was in agreement with the figures reported earlier: colon cancer 10% and
rectal cancer 5–15% [29,37].
Metastatic disease in patients having undergone surgical resection for primary col-
orectal cancer was in our series constant (about 30%) throughout the study period, and
was more aggressively managed over time by neoadjuvant chemotherapy and metastatic
surgery. Overall, the metastasectomy rate for CRC metastases compares favorably with
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those of 12% to 30% reported in other population-based studies [38–40] despite frequent
multisite metastatic patterns. Liver and pulmonary metastasectomy are generally recom-
mended for highly selected subsets of elderly patients due to concerns about the operation
safety and shorter life expectancy. In our series the use metastasectomy was significantly
reduced in the high ACCI group due to patient comorbidities, high age and multisite
metastatic patterns. Metastatic surgery consisted here mostly of liver and lung resections,
being increasingly performed using laparoscopic and thoracoscopic approach. Bowel and
other organ resections were occasionally performed.
OS showed a significant difference in favor of the younger and more fit patients
whereas no differences were observed in CSS and DFS. The difference in OS between the
ACCI groups persisted over time and across all UICC stages. Our results are in line with
previous cohort studies that did find an inverse relationship between age, comorbidity and
survival [9–11]. However, the observation that cancer-related mortality does not decrease
with increasing age strengthens the idea that, although elderly patients have a shorter life
expectancy based on their age and pre-existent conditions, they do still benefit from cancer
treatment. It seems that patients with high ACCI present similar oncological results despite
being treated less intensively in terms of chemotherapy and multimodal treatment.
The results herein reported should be interpreted with some caution, however. First,
the number of patients is relatively small compared to large nationwide population-based
studies. A considerable number of high-risk patients in our study were not operated on
at all, which may contribute to acceptable complications and mortality numbers. Pre-
operative performance and nutritional status, cachexia and the presence of multisite
metastases may have contributed to the selection of these patients. Second, preopera-
tive chemoradiotherapy in rectal cancer might have shifted stage-specific outcome, as
postoperative stage has been used in this study. Patients who respond well to preoperative
treatment have been downstaged, thereby deteriorating survival rates in the higher stages.
Third, for modern treatment of CRC, routine testing of microsatellite instability (MSI) and
RAS/BRAF mutation status has been recommended since 2014, as these have been con-
firmed to be prognostic factors for CRC patients. Our group has previously reported MSI
and RAS/BRAF status as well as immune cell score in a subset of this patient series [41,42]
and, therefore, MSI and RAS/BRAF status as well as detailed histopathological tumor char-
acteristics were not addressed here. Primary tumor sidedness has also been emphasized in
recent years in recognition of the fact that the side of origin plays a role in tumor behavior
and progression [43]. Tumors originating in the right colon are more frequently associated
with female patients, the elderly, BRAF mutations, the enhanced CpG island methylator
phenotype, high microsatellite instability, and high expression of consensus molecular
subtypes 1 and 3 compared with left-side origin tumors. However, in our series there
was no significant survival difference between right- and left-sided colon carcinomas. The
strengths of our study are its population-based design, reliable cancer recurrence data and
detailed follow-up of all patients using direct methods (medical chart review) and national
Death Registry data, thus providing a real-life data of the multimodal management of CRC
and potential results of therapy at the population level.
Despite improvements in multimodal management over time, old age and high comor-
bidity burden affect the use of adjuvant chemotherapy, preoperative (chemo)radiotherapy
and management of metastatic disease and worsen overall survival from CRC.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jcm10081751/s1, Supplementary Figure S1: Trends in multimodal treatment for colon
carcinoma.
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